Aug 16, 2025, 21:54

HRCI–HRB Joint Funding Scheme

Breakthrough Cancer Research invites EOIs for translational/applied cancer research with clear patient impact. Projects must target brain, liver, stomach, lung, ovarian, or early-onset colorectal cancer and demonstrate meaningful Public & Patient Involvement (PPI) and systematic evidence of need.

Eligibility Criteria:

Align with Breakthrough’s mission and show high potential to move into practice/clinical studies.
Research types may include early detection (lab, bioinformatics, AI, big data), drug validation in pre-clinical animal models, pre-clinical studies leading to phase I trials.
Must include active PPI and justify unmet need.
Only the listed cancer sites are in scope for this call.

Funding Details:

Up to EUR 300,000 for 12–36 months.

Deadline:

EOI due to [email protected] by Friday, 15 August 2025, 13:00 Irish time (EOI applications opened 21 July 2025).
Shortlisted full applications via HRB GEMS: 1 Sept – 15 Oct 2025 (deadline 17:00 Irish time).
Reviews: 15 Oct 2025 – 30 Jan 2026; Applicant response: 2–14 Feb 2026; Endorsement: 6 Mar 2026; HRB panel: late May 2026; Notification: June 2026; Project start: 3 Nov 2026 – 1 Jan 2027.

Where to Go for Further Information:

Email: [email protected].
Application information/guidelines.

AI applied research Big Data bioinformatics Breakthrough Cancer Research cancer early detection expression of interest funding HRB HRCI Ireland OncoDaily Oncology phase I trials PPI Preclinical models translational research

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth